Ascendis Pharma (ASND) director adds 500 shares in open-market buys

Rhea-AI Filing Summary

Ascendis Pharma A/S director Jean Jacques Bienaime reported three open-market purchases of Ordinary Shares. On May 29, 2026, he bought a total of 500 shares at prices ranging from $222.30 to $223.76 per share. Following these transactions, he directly holds 600 Ordinary Shares of Ascendis Pharma, with no sales reported in this filing.

Insider Trade Summary

Net Buyer: 500 shares ($111,562)

Net Buy 3 txns

Insider BIENAIME JEAN JACQUES

Role null

Bought 500 shs ($112K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	200	$223.76	$45K
Purchase	Ordinary Shares	200	$222.30	$44K
Purchase	Ordinary Shares	100	$223.50	$22K

Holdings After Transaction: Ordinary Shares — 600 shares (Direct, null)

Footnotes (1)

Key Figures

Total shares purchased: 500 shares Individual trade size 1: 100 shares Individual trade size 2: 200 shares +3 more

6 metrics

Total shares purchased 500 shares Aggregate open-market buys on May 29, 2026

Individual trade size 1 100 shares Open-market purchase at $223.50 per share

Individual trade size 2 200 shares Open-market purchase at $222.30 per share

Individual trade size 3 200 shares Open-market purchase at $223.76 per share

Post-transaction holdings 600 shares Ordinary Shares directly held after final transaction

Net-buy direction 500 shares net-buy Transaction summary for this Form 4

Key Terms

open-market purchase, Ordinary Shares, Form 4, beneficially owned, +1 more

5 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

beneficially owned financial

"total number of shares beneficially owned following the final purchase"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

net-buy financial

"transactionSummary shows a net-buy of 500 shares"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/29/2026		P		200	A	$223.76	600	D
Ordinary Shares	05/29/2026		P		200	A	$222.3	800	D
Ordinary Shares	05/29/2026		P		100	A	$223.5	900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ascendis Pharma (ASND) disclose in this Form 4?

Ascendis Pharma disclosed that director Jean Jacques Bienaime made three open-market purchases totaling 500 Ordinary Shares on May 29, 2026. These buys, reported at prices around $222–$224, increased his direct ownership stake in the company.

How many Ascendis Pharma (ASND) shares did the director buy and at what prices?

Jean Jacques Bienaime bought 500 Ascendis Pharma Ordinary Shares in three trades. The reported purchase prices were $223.50, $222.30, and $223.76 per share, reflecting open-market transactions executed on the same day.

What is Jean Jacques Bienaime’s Ascendis Pharma (ASND) shareholding after these trades?

After the reported purchases, Jean Jacques Bienaime directly holds 600 Ascendis Pharma Ordinary Shares. This figure is disclosed as the total number of shares beneficially owned following the final open-market purchase on May 29, 2026.

Were there any Ascendis Pharma (ASND) share sales reported in this Form 4?

No share sales were reported. The Form 4 shows three open-market purchases and no disposals, with the transaction summary indicating a net-buy of 500 shares and a sell share count of zero for the reporting person.

What does ‘open-market purchase’ mean in the Ascendis Pharma (ASND) Form 4?

An open-market purchase means the director bought shares on a public exchange at prevailing market prices. In this filing, all three transactions are coded as purchases, indicating voluntary buying rather than grants, option exercises, or tax-related share withholdings.